Dechra Pharmaceuticals (LSE:DPH) Additional Paid-In Capital : £596.0 Mil(As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Additional Paid-In Capital?

Dechra Pharmaceuticals's quarterly additional paid-in capital increased from Jun. 2022 (£413.9 Mil) to Dec. 2022 (£594.7 Mil) and increased from Dec. 2022 (£594.7 Mil) to Jun. 2023 (£596.0 Mil).

Dechra Pharmaceuticals's annual additional paid-in capital increased from Jun. 2021 (£411.6 Mil) to Jun. 2022 (£413.9 Mil) and increased from Jun. 2022 (£413.9 Mil) to Jun. 2023 (£596.0 Mil).

Dechra Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Dechra Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Additional Paid-In Capital Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Additional Paid-In Capital

Get a 7-Day Free Trial

277.90

409.30

411.60

413.90

596.00

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Additional Paid-In Capital	Get a 7-Day Free Trial															411.60	413.30	413.90	594.70	596.00

Dechra Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Dechra Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines